Standard InChI: InChI=1S/C55H57F3N12O9/c1-36-10-11-38(31-37(36)13-15-42-33-60-47-8-4-18-61-70(42)47)51(73)62-40-14-12-39(44(32-40)55(56,57)58)34-66-20-22-67(23-21-66)49(72)9-2-5-41-35-68(65-64-41)24-26-78-28-30-79-29-27-77-25-19-59-45-7-3-6-43-50(45)54(76)69(53(43)75)46-16-17-48(71)63-52(46)74/h3-4,6-8,10-12,14,18,31-33,35,46,59H,2,5,9,16-17,19-30,34H2,1H3,(H,62,73)(H,63,71,74)
Protein cereblon/Tyrosine-protein kinase receptor FLT3 27 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Protein cereblon/Tyrosine-protein kinase SRC 2 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Protein cereblon/Stem cell growth factor receptor 1 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Protein cereblon/Platelet-derived growth factor receptor alpha 1 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Associated Targets(non-human)
BaF3 4657 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
H9c2 3506 Activities
Activity Type
Relation
Activity value
Units
Action Type
Journal
PubMed Id
doi
Assay Aladdin ID
Molecule Features
Natural Product: No
Oral: No
Chemical Probe: No
Parenteral: No
Molecule Type: Unknown
Topical: No
First In Class: No
Black Box: No
Chirality: No
Availability: No
Prodrug: No
Drug Indications
MESH ID
MESH Heading
EFO IDs
EFO Terms
Max Phase for Indication
References
Mechanisms of Action
Mechanism of Action
Action Type
target ID
Target Name
Target Type
Target Organism
Binding Site Name
References
Properties
Molecular Weight: 1087.13
Molecular Weight (Monoisotopic): 1086.4324
AlogP:
#Rotatable Bonds:
Polar Surface Area:
Molecular Species:
HBA:
HBD:
#RO5 Violations:
HBA (Lipinski):
HBD (Lipinski):
#RO5 Violations (Lipinski):
CX Acidic pKa:
CX Basic pKa:
CX LogP:
CX LogD:
Aromatic Rings:
Heavy Atoms:
QED Weighted:
Np Likeness Score:
References
1.Yang Y, Gao H, Sun X, Sun Y, Qiu Y, Weng Q, Rao Y.. (2020) Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects., 63 (15):[PMID:32657579][10.1021/acs.jmedchem.0c00967]
